IMPAX Laboratories, Inc. (IPXL) Confirms Patent Challenge Relating to Generic TOVIAZ® 4 Mg and 8 Mg
7/3/2013 8:33:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with TOVIAZ® (fesoterodine fumarate extended-release tablets, 4 mg and 8 mg).
Help employers find you! Check out all the jobs and post your resume.
comments powered by